Vinflunine: A new vision that may translate into antiangiogenic and antimetastatic activity

Anti-Cancer Drugs

Volumn 23, Issue 1, 2012, Pages 1-11

  Anton Aparicio, Luis Miguel ^a,c   Pulido, Enrique Grande ^d   Gallego, Guadalupe Aparicio ^b  

^a CHU A Coruna   (Spain)

^b INIBIC   (Spain)

^c UNIVERSITY OF A CORUÑA   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

angiogenesis; epithelial mesenchymal transition; mechanisms of action; microtubule targeting drug; vinflunine

Indexed keywords

DIMER; POLYMER; TUBULIN; VINCA ALKALOID; VINFLUNINE;

ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL; CAPILLARY; CELL DIVISION; CELL MIGRATION; CELL MOTILITY; CELL POLARITY; CELL SHAPE; CYTOSKELETON; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INTRACELLULAR TRANSPORT; METASTASIS INHIBITION; MICROTUBULE; MITOSIS INHIBITION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL POLARITY; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICROTUBULES; NEOPLASM METASTASIS; TUBULIN; VINBLASTINE; VINCA ALKALOIDS;

EID: 82555170343     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834d237b     Document Type: Review

References (110)

1. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-1154.
2. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377:914-923.
3. Blasko G, Cordell GA. Isolation, structure elucidation and biosynthesis of the bisindole alkaloids of Cantharanthus. In: Brossi A, Suffness M, editors. The alkaloids-antitumor bisindole alkaloids from Catharanthus roseus (L). San Diego, California: Academic Press, Inc. 1990; pp. 1-76.
4. Noble RL, Beer CT, Cutts JH. Role of chance observations in chemotherapy: Vinca rosea. Ann N Y Acad Sci 1958; 76:882-894.
5. Fahy J, Hellier P, Breillout F, Bailly C. Vinflunine: discovery and synthesis of a novel microtubule inhibitor. Semin Oncol 2008; 35:S3-S5. (Pubitemid 351766730)
6. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 2001; 60:225-232. (Pubitemid 32595250)
7. Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA,Wilson L. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 2000; 60:5045-5051.
8. Kruczynski A, Barret JM, Etiévant C, Colpaert F, Fahy J, Hill BT. Antimitotic and tubulin-interacting properties of vinflunine, a novel Vinca alkaloid. Biochem Pharmacol 1998; 55:635-648. (Pubitemid 28077822)
9. Etiévant C, Kruczinsky A, Chansard N, Cabrol N, Astruc J, Chazottes E, Hill BTL. Characterization of apoptosis induced by vinflunine, a novel fluorinated Vinca alkaloid, in sensitive and vinflunine resistant P388 tumor cells: concomitant cell cycle analysis. Proc Am Assoc Cancer Res 1998; 39:166 (Abstract 1140).
10. Lobert S, Ingram JW, Hill BT, Correia JJ. A comparison of thermodynamic parameters for vinorelbine and vinflunie-induced tubulin self-association by sedimentation. Mol Pharmacol 1998; 53:908-915. (Pubitemid 28244079)
11. Etiévant C, Barret JM, Kruczinsky A, Perrin D, Hill BT. Vinflunine (200, 200- difuoro- 330-40-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs 1999; 16:3-17. (Pubitemid 28379411)
12. Mamtani R, Vaughn DJ. Vinflunine in the treatment of advanced bladder cancer. Expert Rev Anticancer Ther 2011; 11:13-20.
13. Gerullis H, Ecke T, Eimer C, Wishahi M, Otto T. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review. Anticancer Drugs 2011; 22:9-17.
14. Frampton JE, Moen MD. Vinflunine. Drugs 2010; 70:1283-1293.
15. Jordan MA, Himes RH,Wilson L. Comparison of the effects of vinblastine, vincrisine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res 1985; 45:2741-2747. (Pubitemid 15232744)
16. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991; 51:2212-2222.
17. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9:790-803.
18. Toso RJ, Jordan MA, Farrell KW, Matsumoto B, Wilson L. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry 1993; 32:1285-1293. (Pubitemid 23070652)
19. Lobert S, Vulevic B, Correia JJ. Interaction of Vinca alkaloids with tubulin: a comparison of vinblastine, vincristine and vinorelbine. Biochemistry 1996; 35:6806-6814. (Pubitemid 26172439)
20. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Med 1993; 62:385-427. (Pubitemid 23237876)
21. Hill BT. Differing patterns of cross-resistance resulting from exposure to specific antitumour drugs or to radiation in vitro. Cytotechnology 1993; 12:265-288.
22. Kruczynski A, Etiévant C, Chansard N, Cabrol N, Astruc J, Chazottes E, et al. Induction of apoptosis by vinflunine, a novel fluorinated Vinca alkaloid. 10th NCI-EORTC Symposium on New Drugs Cancer Ther 1998; A391:102.
23. Kruczynski A, Etiévant C, Perrin D, Chansard N, Duflos A, Hill BT. Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development. Br J Cancer 2002; 86:143-150. (Pubitemid 34146355)
24. Stone AA, Chambers TC. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signalling pathways in human Kβ3 carcinoma cells. Exp Cell Res 2000; 254:110-119. (Pubitemid 30066737)
25. Wang LG, Liu XM, Kreis W, Budman DR. The effect of anti-microtubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999; 44:355-361. (Pubitemid 29455579)
26. Pourroy B, CarréM, HonoréS, Bourgarel-Rey V, Kruczynski A, Briand C, et al. Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathways. Mol Pharmacol 2004; 66:580-591. (Pubitemid 39329257)
27. AndréN, CarréM, Brasseur G, Pourroy B, Kovacic H, Briand C, et al. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett 2002; 532:256-260. (Pubitemid 35375900)
28. CarréM, Braguer D. Microtubule damaging agents and apoptosis. In: Fojo T, editor. Microtubules and disease. Humana Press; 2006.
29. Pasquier E, CarréM, Pourroy B, Camoin L, Rebaï O, Briand C, et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004; 3:1301-1310. (Pubitemid 39440174)
30. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57:229-233. (Pubitemid 27038278)
31. Shore GC, Viallet J. Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology 2005; 1:1226-1230.
32. Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, et al. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 2003; 64:51-58. (Pubitemid 36759817)
33. Estève MA, CarréM, Bourgarel-Rey V, Kruczynski A, Raspaglio G, Ferlini C, et al. Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. Mol Cancer Ther 2006; 5:2824-2833. (Pubitemid 44849009)
34. Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the MAC 15: a transplantable adenocarcinoma model. Br J Cancer 2001; 84:290-295. (Pubitemid 32113459)
35. Braguer D, Barret JM, McDaid H, Kruczinsky A. Antitumor activity of vinflunine: effector pathways and potential for synergies. Semin Oncol 2008; 35:S13-S21. (Pubitemid 351758953)
36. CarréM, AndréN, Carles G, Borghi H, Brichese L, Briand C, et al. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem 2002; 277:33664-33669.
37. Jordan MA,Wilson L. Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations. Biochemistry 1990; 29:2730-2739. (Pubitemid 20122607)
38. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Macromolecules: structure, shape, and information. In: Alberts B, editor. Molecular biology of the cell. 4th ed. Oxford, UK: Garland Publishing. 2002; pp. 89-138.
39. Jordan MA, Wilson L. Microtubules as a target for anti-cancer drugs. Nat Rev Cancer 2004; 4:253-265.
40. Jordan MA, Horwitz SB, Lobert S, Correia JJ. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunie. Semin Oncol 2008; 35:S6-S12. (Pubitemid 351758949)
41. Hays TS, Salmon ED. Poleward force at the kinetochore in metaphase depends on the number of kinetochore microtubules. J Cell Biol 1990; 110:391-404.
42. Nicklas RB, Ward SC, Gorbsky GJ. Kinetochore chemistry is sensitive to tension and may link mitotic forces to a cell cycle checkpoint. J Cell Biol 1995; 130:929-939.
43. Mitchison TJ. Polewards microtubule flux in the mitotic spindle: evidence from photoactivation of fluorescence. J Cell Biol 1989; 109:637-652. (Pubitemid 19197026)
44. Waters JC, Mitchison TJ, Rieder CL, Salmon ED. The kinetochore microtubule minus-end disassembly associated with poleward flux produces a force that can do work. Mol Biol Cell 1996; 7:1547-1558. (Pubitemid 26339728)
45. Sackett DL. Structure and function in the 'Tubulin dimer and the role of the acidic carboxyl terminus'. In: Biswas BB, Siddharthe R, editors. Subcellular biochemistry-Proteins: structure, function and engineering. New York: Plenum Press. 1995; pp. 255-302.
46. Luduena RF. Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 1998; 178:207-275. (Pubitemid 128717548)
47. Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev 2000; 16:89-111. (Pubitemid 32037501)
48. Schwartz PM, Liggins JR, Ludueña RF. βtubulin isotypes purified from bovine brain have different relative stabilities. Biochemistry 1998; 37:4687-4692. (Pubitemid 28217188)
49. Sirotnak FM, Danenberg KD, Chen J, Fritz F, Danenberg PV. Markedly decreased binding of vincristine to tubulin in Vinca alkaloid-resistant Chinese hamster cells is associated with selective overexpression of alpha and beta tubulin isoforms. Biochem Biophys Res Commun 2000; 269:21-24. (Pubitemid 30440247)
50. Maccioni RB, Cambiazo V. Role of microtubule-associated proteins in the control of microtubule assembly. Physiol Rev 1995; 75:835-864.
51. Verdier-Pinard P, Wang F, Burd B, Angeletti RH, Horwitz SB, Orr GA. Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry. Biochemistry 2003; 42:12019-12027. (Pubitemid 37280652)
52. Cassimeris L. The oncoprotein 18/stahmin family of microtubule destabilizers. Curr Opin Cell Biol 2002; 14:18-24. (Pubitemid 34131652)
53. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Topnin S, Marchisio PC, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002; 62:2462-2467. (Pubitemid 34462718)
54. Maney T, Waagenbach M, Wordeman L. Molecular dissection of the microtubule depolymerizing activity of mitotic centromere-associated kinesin. J Biol Chem 2001; 276:34753-34758.
55. Spittle C, Charrasse S, Larroque C, Cassimeris L. The interaction of TOGp with microtubules and tubulin. J Biol Chem 2000; 275:20748-20753. (Pubitemid 30457664)
56. Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 1997; 13:83-117. (Pubitemid 28034521)
57. McNally FJ. Modulation of microtubule dynamics during the cell cycle. Curr Opin Cell Biol 1996; 8:23-29. (Pubitemid 26059700)
58. Nogales E. Structural insight into microtubule function. Annu Rev Biophys Biomol Struct 2001; 30:397-420.
59. Mitchison TJ, Kirschner M. Dynamic instability of microtubule growth. Nature 1984; 312:237-242. (Pubitemid 15201998)
60. Hayden JJ, Bowser SS, Rieder C. Kinetochores capture astral microtubules during chromosome attachment to the mitotic spindle: direct visualization in live newt cells. J Cell Biol 1990; 111:1039-1045.
61. Skibbens RV, Skeen VP, Salmon ED. Directional instability of kinetochore mobility during chromosome congression and segregation in mitotic newt lung cells: a push-pull mechanism. J Cell Biol 1993; 122:859-875. (Pubitemid 23241095)
62. Margolis RL,Wilson L. Microtubule treadmilling: what goes around comes around. BioEssays 1998; 20:830-836. (Pubitemid 28486019)
63. Rodionov VI, Nadezhina E, Borisy GG. Centrosomal control of microtubule dynamics. Proc Natl Acad Sci USA 1999; 96:115-120.
64. Panda D, Miller HP, Wilson L. Rapid treadmilling of MAP-free brain microtubules in vitro and its suppression by tau. Proc Natl Acad Sci USA 1999; 96:12459-12464. (Pubitemid 29513524)
65. Mitchison TJ, Salmon ED. Poleward kinetochore fiber movement occurs during both metaphase and anaphase-A in newt lung cell mitosis. J Cell Biol 1992; 119:569-582.
66. Hill SA, Longergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: antivascular effects in a murine tumour. Eur J Cancer 1993; 29:1320-1324. (Pubitemid 23169906)
67. Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorelbine: an overview. Cancer Treat Rev 1996; 22:127-142. (Pubitemid 26235725)
68. Hill BT, Fiebig HH, Waud WR, Poupon MF, Colpaert F, Kruczinsky A. Superior in-vivo experimental antitumour activity of vinflunine, relative to vinorelbine, I a panel of human tumour xenografts. Eur J Cancer 1999; 35:512-520. (Pubitemid 29151954)
69. Lavielle G, Hautefaye P, Schaeffer C, Boutin JA, Cudennec CA, Pierre AJ. New alpha-amino phosphonic acid derivatives of vinblastine: chemistry and antitumor activity. Med Chem 1991; 34:1998-2003.
70. Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, et al. Anti-angiogenic, antivascular-disrupting and anti-metastatic activities of vinflunine, the latest Vinca alkaloid in clinical development. Eur J Cancer 2006; 42:2821-2832. (Pubitemid 44584664)
71. Kruczinsky A, Colpaert F, Tarayre J-P, Mouillard P, Fahy J, Hill BT. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 1998; 41:437-447. (Pubitemid 28140706)
72. Bonfil RD, Russo DM, Binda MM, Delgado FM, Vicenti M. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol 2002; 7:159-166.
73. Catalogue of somatic mutations in cancer. Available from: http:// www.sanger.ac.uk/perl/genetics/CGP/cosmic.
74. Knowles MA. Role of FGFR3 in urothelial carcinoma: biomarker and potential therapeutic target. World J Urol 2007; 25:581-593.
75. Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, et al. Phase II study of vinflunine in bladder cancer patients progression after line platinum-containing regimen. Br J Cancer 2006; 94:1395-1401. (Pubitemid 43772272)
76. Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma. Cancer 2009; 115:4110-4117.
77. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27:4454-4461.
78. Souquet PJ, Krzakowski M, Ramlau R, Sun XS, Lopez-Vivanco G, Puozzo C, et al. Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2010; 11:105-113.
79. Bennouna J, Breton JL, Tourani JM, Ottensmeier C, O'Brien M, Kosmidis P, et al. Vinflunine - an active chemotherapy for treatment of advanced nonsmall- cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer 2006; 94:1383-1388. (Pubitemid 43772270)
80. Krzakowski M, Ramlau R, Jassem J, Szczesna A, Zatloukal P, von Pawel J, et al. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinumcontaining chemotherapy. J Clin Oncol 2010; 28:2167-2173.
81. Campone M, Cortes-Funes H, Vorobiof D, Martin M, Slabber CF, Ciruelos E, et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer 2006; 95:1161-1166. (Pubitemid 44658478)
82. Fumoleau P, Cortés-Funes H, Taleb AB, Chan S, Campone M, Pouget JC, et al. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy. Am J Clin Oncol 2009; 32:375-380.
83. Yardley DA, McCleod M, Schreiber F, Murphy P, Patton J, Thompson DS, et al. A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer. Cancer Invest 2010; 28:925-931.
84. Hainsworth JD, Meluch AA, Lane CM, Spigel DR, Burris HA 3rd, Gandhi JG, et al. Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon Research Consortium. Cancer Invest 2010; 28:275-279.
85. Talbot DC, Margery J, Dabouis G, Dark G, Taylor H, Boussemart H, et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 2007; 25:4751-4756. (Pubitemid 350086477)
86. Olver IN, Byrne MJ,Walpole E, Vorobiof D, Jacobs C, Maart K, et al. Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma. Eur J Cancer 2007; 43:1829-1832. (Pubitemid 47243653)
87. Goldstein D, Ackland SP, Bell DR, Olver IN, Davis ID, Rosenthal MA, et al. Phase II study of vinflunine in patients with metastatic renal cell carcinoma. Invest New Drugs 2006; 24:429-434. (Pubitemid 43876079)
88. Hay ED. An overview of epithelio-mensenchymal transformation. Acta Anat 1995; 154:8-20.
89. Thiery JP. Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2002; 2:442-454.
90. Kalluri R, Weinberg RA. The basis of epithelial-mesenchymal transition. J Clin Invest 2009; 119:1420-1428.
91. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996; 84:359-369. (Pubitemid 26058561)
92. Watanabe T, Noritake J, Kaibuchi K. Regulation of microtubules in cell migration. Trends Cell Biol 2005; 15:76-83. (Pubitemid 40188217)
93. Ballestrem C, Magid N, Zonis J, Shtutman M, Bershadsky A. Interplay between the actin cytoskeleton, focal adhesions, and microtubules. In: Ridley A, Peckham M, Clark P, editors. Cell motility: from molecules to organisms. Chichester: John Wiley and Sons, Ltd. 2004; pp. 75-99.
94. Liu SM, Magnusson KE, Sundqist T. Microtubules are involved in transport of macro-molecules by vesicles in cultured bovine aortic endothelial cells. J Cell Physiol 1993; 156:311-316. (Pubitemid 23244094)
95. Waterman-Storer CM, Salmon E. Positive feedback interactions between microtubule and actin dynamics during cell motility. Curr Opin Cell Biol 1999; 11:61-67. (Pubitemid 29084133)
96. Zhou X, Li J, Kucik DF. The microtubule cytoskeleton participates in control of b2 integrin avidity. J Biol Chem 2001; 76:44762-44769.
97. Whipple RA, Matrone MA, Cho EH, Balzer EM, Vitolo MI, Yoon JR, et al. Epithelial-to-mesenchymal transition promotes tubulin detyrosination and microtentacles that enhance endothelial engagement. Cancer Res 2010; 70:8127-8137.
98. Manna T, Honnappa S, Steinmetz MO, Wilson L. Suppression of microtubule dynamic instability by the +TIP protein EB1 and its modulation by the CAP-Gly domain of p150(Glued). Biochemisty 2008; 47:779-786. (Pubitemid 351195449)
99. Lansbergen G, Akhmanova A. Microtubule pus end: a hub of cellular activities. Traffic 2006; 7:499-507. (Pubitemid 44026748)
100. Margolis RL, Rauch CT, Job D. Purification and assay of a 145-kDa protein (STOP 145) with microtubule-stabilizing and motility behavior. Proc Natl Acad Sci USA 1986; 83:639-643. (Pubitemid 16035530)
101. Pabiom M, Job D, Margolis RL. Sliding of STOP proteins on microtubules. Biochemistry 1984; 23:6642-6648. (Pubitemid 15167741)
102. Bosc C, Frank R, Denarier E, Ronjat M, Schweitzer A, Wehland J, et al. Identification of novel bifunctional calmodulin-binding and microtubulestabilizing motifs in STOP proteins. J Biol Chem 2001; 276: 30904-30913.
103. Bosch C, Oenarier E, Andrieux A, Job D. Stop proteins. Cell Struct Funct 1999; 24:393-399.
104. 2+-calmodulin regulated effectors of microtubule stability in bovine brain. Biochemistry 1992; 31:8849-8855.
105. 2+-calmodulin regulated effectors of mirotubule stability in neural tissues. Biochim Biophys Acta 1992; 1160:113-119.
106. Erent M, Pagakis S, Browne JP, Bayley PM. Association of calmodulin with cytoskeletal structures at different stages of HeLa cell division, visualized by a calmodulin-EGFP fusion protein. Mol Cell Biol Res Commun 1999; 1:209-215. (Pubitemid 129532305)
107. Li CJ, Heim R, Lu P, Pu Y, Tsien RY, Chang DC. Dynamic redistribution of calmodulin in HeLa cells during cell division as revealed by a GFP-calmodulin fusion protein technique. J Cell Sci 1999; 112: 1567-1577. (Pubitemid 29261318)
108. 2+-calmodulin binding interactions of the microtubuleassociated protein F-STOP. Biochemistry 2003; 42:11484-11493. (Pubitemid 37205743)
109. HonoréS, Pagano A, Gautier G, Bourgaret-Rey V, Verdier-Pinard P, Civilett K, et al. Antiangiogenic vinflunine effects EB1 localization and microtubule targeting to adhesion sites. Mol Cancer Ther 2008; 7: 2080-2089.
110. Makarov AA, Tsvetkov PO, Villard C, Esquqieu D, Pourroy B, Fahy J, et al. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP. Biochemistry 2007; 46:14899-14906. (Pubitemid 350308881)